Cure8 news brief
Keeping IBD well controlled before and during pregnancy lowers the risk of adverse outcomes for both parent and baby; understanding which medications are safe and which should be stopped is crucial for family planning.
People with IBD who are planning pregnancy, pregnant patients with IBD, caregivers/partners, and clinicians managing IBD in pregnancy.
The article contrasts outdated advice to avoid pregnancy with current evidence showing most biologics and several immunosuppressants are not linked to major increases in birth defects or miscarriage; it cites the PIANO study as a key source.
It notes methotrexate must be stopped well before conception and that JAK inhibitors are generally advised against based on animal data. Corticosteroids may be used for flares but should be minimized when possible.
Routine assessment of inflammation before conception and use of tools such as intestinal ultrasound during pregnancy are recommended to guide care. Talk with your care team Discuss family planning with your gastroenterologist and obstetrician so medication plans and disease monitoring are coordinated.
Aim for disease remission before conception and close follow-up during pregnancy to reduce risks associated with active inflammation.
This article summarizes contemporary expert opinion and research (including the PIANO study) and refers to a global consensus expected in 2025; it is a news-summary rather than a clinical guideline. Individual treatment decisions should be made with clinicians.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Most people with IBD can have children safely with modern treatments and planning; uncontrolled disease poses greater risks to pregnancy than continuing most IBD medications. Planning and specialist input before...
Pregnancy planning and contraception are important for people with IBD because active disease at conception is linked to worse pregnancy outcomes. The article shows many women with IBD are unsure about how contraception...
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy)...
